Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review

IF 13.4 Q1 GERIATRICS & GERONTOLOGY Lancet Healthy Longevity Pub Date : 2024-03-04 DOI:10.1016/S2666-7568(24)00007-2
Kathryn Nicholson PhD , Winnie Liu BSc , Daire Fitzpatrick MD , Kate Anne Hardacre BMSc , Sarah Roberts MD , Jennifer Salerno PhD , Prof Saverio Stranges MD PhD , Martin Fortin MD MSc , Prof Dee Mangin MBCHB DPH
{"title":"Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review","authors":"Kathryn Nicholson PhD ,&nbsp;Winnie Liu BSc ,&nbsp;Daire Fitzpatrick MD ,&nbsp;Kate Anne Hardacre BMSc ,&nbsp;Sarah Roberts MD ,&nbsp;Jennifer Salerno PhD ,&nbsp;Prof Saverio Stranges MD PhD ,&nbsp;Martin Fortin MD MSc ,&nbsp;Prof Dee Mangin MBCHB DPH","doi":"10.1016/S2666-7568(24)00007-2","DOIUrl":null,"url":null,"abstract":"<div><p>Multimorbidity (multiple conditions) and polypharmacy (multiple medications) are increasingly common, yet there is a need to better understand the prevalence of co-occurrence. In this systematic review, we examined the prevalence of multimorbidity and polypharmacy among adults (≥18 years) and older adults (≥65 years) in clinical and community settings. Six electronic databases were searched, and 87 studies were retained after two levels of screening. Most studies focused on adults 65 years and older and were done in population-based community settings. Although the operational definitions of multimorbidity and polypharmacy varied across studies, consistent cut-points (two or more conditions and five or more medications) were used across most studies. In older adult samples, the prevalence of multimorbidity ranged from 4·8% to 93·1%, while the prevalence of polypharmacy ranged from 2·6% to 86·6%. High heterogeneity between studies indicates the need for more consistent reporting of specific lists of conditions and medications used in operational definitions.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 4","pages":"Pages e287-e296"},"PeriodicalIF":13.4000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000072/pdfft?md5=8a7dd41890037b965e15a057ab456b6c&pid=1-s2.0-S2666756824000072-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Healthy Longevity","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666756824000072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Multimorbidity (multiple conditions) and polypharmacy (multiple medications) are increasingly common, yet there is a need to better understand the prevalence of co-occurrence. In this systematic review, we examined the prevalence of multimorbidity and polypharmacy among adults (≥18 years) and older adults (≥65 years) in clinical and community settings. Six electronic databases were searched, and 87 studies were retained after two levels of screening. Most studies focused on adults 65 years and older and were done in population-based community settings. Although the operational definitions of multimorbidity and polypharmacy varied across studies, consistent cut-points (two or more conditions and five or more medications) were used across most studies. In older adult samples, the prevalence of multimorbidity ranged from 4·8% to 93·1%, while the prevalence of polypharmacy ranged from 2·6% to 86·6%. High heterogeneity between studies indicates the need for more consistent reporting of specific lists of conditions and medications used in operational definitions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人和老年人中多病和多药的流行情况:系统综述。
多病(多种疾病)和多药(多种药物)越来越常见,但仍需更好地了解其并发症的流行情况。在这篇系统性综述中,我们研究了临床和社区环境中成年人(≥18 岁)和老年人(≥65 岁)多病和多药并发症的发生率。我们检索了六个电子数据库,经过两级筛选后保留了 87 项研究。大多数研究以 65 岁及以上的成年人为研究对象,并且是在以人口为基础的社区环境中进行的。虽然不同研究对多病症和多药方的操作定义各不相同,但大多数研究都采用了一致的切点(两种或两种以上病症和五种或五种以上药物)。在老年人样本中,多病患病率从 4-8% 到 93-1% 不等,而多重用药患病率从 2-6% 到 86-6% 不等。研究之间的高度异质性表明,有必要对操作定义中使用的具体病症和药物清单进行更加一致的报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lancet Healthy Longevity
Lancet Healthy Longevity GERIATRICS & GERONTOLOGY-
CiteScore
16.30
自引率
2.30%
发文量
192
审稿时长
12 weeks
期刊介绍: The Lancet Healthy Longevity, a gold open-access journal, focuses on clinically-relevant longevity and healthy aging research. It covers early-stage clinical research on aging mechanisms, epidemiological studies, and societal research on changing populations. The journal includes clinical trials across disciplines, particularly in gerontology and age-specific clinical guidelines. In line with the Lancet family tradition, it advocates for the rights of all to healthy lives, emphasizing original research likely to impact clinical practice or thinking. Clinical and policy reviews also contribute to shaping the discourse in this rapidly growing discipline.
期刊最新文献
Highlights of the EuGMS congress 2024. Frailty screening with comprehensive geriatrician-led multidisciplinary assessment for older adults during emergency hospital attendance in Ireland (SOLAR): a randomised controlled trial. Rethinking emergency care for older adults living with frailty. Navigating complex care for older women with HIV: role of geriatrician support. Integrating immunisation into a global strategy for healthy ageing.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1